| [1] |
Böcker W, Moll R, Poremba C, et al. Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept[J]. Lab Invest,2002,82(6):737-746.
|
| [2] |
Bocker W, Buerger H. Evidence of progenitor cells of glandular and myoepithelial cell lineages in the human adult female breast epithelium:a new progenitor (adult stem) cell concept[J]. Cell Prolif, 2003,36 Suppl 1:73-84.
|
| [3] |
Yang X, Wang H, Jiao B. Mammary gland stem cells and their application in breast cancer[J]. Oncotarget, 2017, 8(6):10 675-10 691.
|
| [4] |
Lacroix-Triki M, Mery E, Voigt JJ, et al. Value of cytokeratin 5/6 immunostaining using D5/16 B4 antibody in the spectrum of proliferative intraepithelial lesions of the breast. A comparative study with 34betaE12 antibody [J]. Virchows Arch, 2003, 442 (6):548-554.
|
| [5] |
Inanc M, Ozkan M, Karaca H, et al. Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer[J]. Med Oncol,2014,31(1):801.
|
| [6] |
Raju U, Crissman JD, Zarbo RJ, et al. Epitheliosis of the breast. An immunohistochemical characterization and comparison to malignant intraductal proliferations of the breast[J]. Am J Surg Pathol, 1990,14(10):939-947.
|
| [7] |
de Deus Moura R, Wludarski SC, Carvalho FM, et al.Immunohistochemistry applied to the differential diagnosis between ductal and lobular carcinoma of the breast[J]. Appl Immunohistochem Mol Morphol,2013,21(1):1-12.
|
| [8] |
Moriya T, Kozuka Y, Kanomata N, et al. The role of immunohistochemistry in the differential diagnosis of breast lesions[J].Pathology,2009,41(1):68-76.
|
| [9] |
Burns WC,Thomas MC. The molecular mediators of type 2 epithelial to mesenchymal transition (EMT) and their role in renal pathophysiology[J].Expert Rev Mol Med,2010,12: e17.
|
| [10] |
Lerwill MF.Current practical applications of diagnostic immunohistochemistry in breast pathology [J]. Am J Surg Pathol,2004,28(8):1076-1091.
|
| [11] |
Bratthauer GL, Moinfar F, Stamatakos MD, et al. Combined E-cadherin and high molecular weight cytokeratin immunoprofile differentiates lobular, ductal, and hybrid mammary intraepithelial neoplasias [J]. Hum Pathol,2002,33(6):620-627.
|
| [12] |
Aiad HA, Abd El-Halim Kandil M, Abd El-Wahed MM, et al.Dignostic role of p63 immunostaining in fine needle aspiration cytology of different breast lesions [J]. Acta Cytol,2011,55(2):149-157.
|
| [13] |
Tse GM, Ni YB, Tsang JY, et al. Immunohistochemistry in the diagnosis o papillary lesions o the breast [J]. Histopathology, 2014,65(6):839-853.
|
| [14] |
Altaf FJ, Mokhtar GA, Emam E, et al. Metaplastic carcinoma of the breast: an immunohistochemical study [J]. Diagn Pathol, 2014,9:139.
|
| [15] |
Hilson JB, Schnitt SJ, Collins LC. Phenotypic alterations in ductal carcinoma in situ-associated myoepithelial cells: biologic and diagnostic implications [J]. Am J Surg Pathol,2009,33(2):227-232.
|
| [16] |
Sarkar S, Kanoi A, Bain J, et al. Correlation between cyclin D1 expression and standard clinicopathological variables in invasive breast cancer in Eastern India [J]. South Asian J Cancer, 2015, 4(4):155-159.
|
| [17] |
李文华. 乳腺肌上皮细胞标记的研究进展[J]. 临床与实验病理学杂志,2015,31(3):309-312.
|
| [18] |
Tse GM, Tan PH, Lui PC, et al. The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast[J]. J Clin Pathol, 2007,60(3):315-320.
|
| [19] |
Ye N, Wang B, Quan ZF, et al. The research progress of the interactions between miRNA and Wnt/beta-catenin signaling pathway in breast cancer of human and mice [J]. Asian Pac J Cancer Prev,2014,15(3):1075-1079.
|
| [20] |
Mei XD, Su H, Song J, et al. Prognostic significance of β-catenin expression in patients with non-small cell lung cancer: a meta-analysis[J]. Biosci Trends,2013,7(1):42-49.
|
| [21] |
Henry C, Quadir A, Hawkins NJ, et al. Expression of the novel Wnt receptor ROR2 is increased in breast cancer and may regulate both βcatenin dependent and independent Wnt signaling [J]. J Cancer Res Clin Oncol,2015,141(2):243-254.
|
| [22] |
Kim H, Seo EM, Sharma AR, et al. Regulation of Wnt signaling activity for growth suppression induced by quercetin in 4T1 murine mammary cancer cells[J]. Int J Oncol,2013,43(4):1319-1325.
|
| [23] |
Guo L, Liu S, Jakulin A, et al. Positive expression of cyclin D1 is an indicator for the evaluation of the prognosis of breast cancer[J]. Int J Clin Exp Med,2015,8(10):18 656-18 664.
|
| [24] |
Bilalovic' N, Vranic' S,Basic' H,et al. Immunohistochemical evaluation of cyclin D1 in breast cancer [J]. Croat Med J, 2005, 46(3):382-388.
|
| [25] |
Li Z, Cui J, Yu Q, et al. Evaluation of CCND1 amplification and CyclinD1 expression:diffuse and strong staining of CyclinD1 could have same predictive roles as CCND1 amplification in ER positive breast cancers[J]. Am J Transl Res,2016,8(1):142-153.
|
| [26] |
Blick T, Widodo E, Hugo H, et al. Epithelial mesenchymal transition traits in human breast cancer cell lines [J]. Clin Exp Metastasis,2008,25(6):629-642.
|
| [27] |
Christofori G. New signals from the invasive front [J]. Nature, 2006,441(7092):444-450.
|
| [28] |
Tang D, Xu S, Zhang Q, et al. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer [J]. Med Oncol,2012,29(2):526-533.
|
| [29] |
Kourtidis A, Yanagisawa M, Huveldt D, et al. Pro-tumorigenic phosphorylation of p120 catenin in renal and breast cancer[J]. PLoS One,2015,10(6): e0129964.
|
| [30] |
Liu X, Yi C, Wen Y, et al. Interactions between MUIC and P120 catenin regulate dynamic features of cell adhesion, motillty, and metastasis [J]. Cancer Res,2014,74(5):1609-1620.
|
| [31] |
Ramos EA, Silva CT, Manica GC, et al. Worse prognosis in breast cancer patients can be predicted by immunohistochemical analysis of positive MMP-2 and negative estrogen and progesterone receptors[J].Rev Assoc Med Bras,2016,62(8):774-781.
|
| [32] |
Bouchalova K, Kharaishvili G, Bouchal J, et al. Triple negative breast cancer - BCL2 in prognosis and prediction. Review[J]. Curr Drug Targets,2014,15(12):1166-1175.
|
| [33] |
Eom YH, Kim HS, Lee A, et al. BCL2 as a subtype-specific prognostic marker for breast cancer[J]. J Breast Cancer, 2016, 19(3):252-260.
|
| [34] |
Min KW, Kim DH, Do SI, et al. High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer[J]. Postgrad Med J,2016,92(1094):707-714.
|
| [35] |
Hlupic' L, Jakic' -Razumovic' J, Bozikov J, et al. Prognosis value of diferent factors in breast carcinoma[J]. Tumori, 2004, 90 (1):112-119.
|
| [36] |
Feng J, Li L, Zhang N, et al. Androgen and AR contribute to breast cancer development and metastasis: an insight of mechanisms[J].Oncogene,2017,36(20):2775-2790.
|
| [37] |
Huang W, Nie W, Zhang W, et al. The expression status of TRX,AR, and cyclin D1 correlates with clinicopathological characteristics and ER status in breast cancer[J]. Onco Targets Ther, 2016, 9:4377-4385.
|
| [38] |
Brenton JD, Carey LA, Ahmed AA, et al. Molecular classification and molecular forecasting of breast cancer: ready for clinical application?[J]. J Clin Oncol,2005,23(29):7350-7360.
|
| [39] |
Savage K, Leung S, Todd SK, et al. Distribution and significance of caveolin2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis [J]. Breast Cancer Res Treat,2008,110(2):245-256.
|
| [40] |
Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triplenegative phenotype [J]. Clin Cancer Res,2008,14(5):1368-1376.
|
| [41] |
Inanc M, Ozkan M, Karaca H, et al. Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer [J]. Med Oncol,2014,31(1):801.
|
| [42] |
Masuda H,Zhang D,Bartholomeusz C,et al. Role of epidermal growth factor receptor in breast cancer [J]. Breast Cancer Res Treat, 2012,136(2):331-345.
|
| [43] |
Lialiaris TS, Georgiou G, Sivridis E, et al. Prognostic and predictive factors of invasive ductal breast carcinomas [J]. J BUON, 2010,15(1):79-88.
|
| [44] |
Calza S, Hall P, Auer G, et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients [J]. Breast Cancer Res,2006,8(4): R34.
|
| [45] |
Bartlett JM, McConkey CC, Munro AF, et al. Predicting anthracycline benefit:TOP2A and CEP17-not only but also[J]. J Clin Oncol,2015,33(15):1680-1687.
|
| [46] |
Wang K, Deng QT, Liao N, et al. Tau expression correlated with breast cancer sensitivity to taxanes-based neoadjuvant chemotherapy[J]. Tumour Biol,2013,34(1):33-38.
|
| [47] |
Yunokawa M, Koizumi F,Kitamura Y,et al. Efficacy of everolimus,a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells [J]. Cancer Sci,2012,103(9):1665-1671.
|
| [48] |
Gomez-Fernandez C, Jorda M,Delgado PI,et al. Thyroid transcription factor 1: a marker for lung adenocarcinoma in body cavity fluids [J].Cancer,2002,96(5):289-293.
|
| [49] |
Gown AM, Fulton RS, Kandalaft PL. Markers of metastatic carcinoma of breast origin[J]. Histopathology,2016,68(1):86-95.
|
| [50] |
Ghaffari SR, Sabokbar T, Tahmasebi S, et al. Combining mammaglobin and carcinoembryonic mRNA markers for early detection of micrometastases from breast cancers-a molecular study of 59 patients[J]. Asian Pac J Cancer Prev,2006,7(3):396-398.
|